Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jan 20;18(1):e0280893. doi: 10.1371/journal.pone.0280893

Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspective

Aggrey David Mukose 1,2,*, Hilde Bastiaens 2,3, Fredrick Makumbi 1, Esther Buregyeya 4, Rose Naigino 5, Joshua Musinguzi 6, Jean-Pierre Van Geertruyden 2, Rhoda K Wanyenze 4
Editor: Desmond Kuupiel7
PMCID: PMC9858842  PMID: 36662894

Abstract

Introduction

Uganda has implemented lifelong antiretroviral therapy for the prevention of mother-to-child HIV transmission since September 2012. Implementation of this strategy has been met with health provider and client challenges which have persisted up to date. This study explored providers’ perspectives on the challenges and countermeasures of the implementation and scale-up of lifelong ART among pregnant and breastfeeding women.

Methods

A qualitative descriptive study was conducted whereby 54 purposively selected participants from six facilities in three districts of Central Uganda namely; Masaka, Mityana, and Luwero were recruited. A key informant interview guide was used to collect data from the study participants. The data were thematically analysed using Atlas-ti, Version 7.

Results

Study participants reported challenges under the themes of 1) inadequacy of HIV service delivery (lack of relevant training, health provider shortages, inadequate counselling, stock-outs of essential HIV commodities); 2) Non-utilization of HIV services (Non-disclosure of HIV- positive results, denial of HIV positive results, fear to be followed up, unwillingness to be referred, large catchment area, lack of transport); and 3) Suboptimal treatment adherence (fear of ART side effects, preference for traditional medicines, low male partner involvement in care and treatment). Strategies such as on-job training, mentorship, task shifting, redistribution of HIV commodities across facilities, accompanying of women to mother-baby care points, ongoing counseling of women, peers, and family support groups were commonly used countermeasures.

Conclusions

This study highlights key challenges that health providers face in implementing lifelong antiretroviral therapy services among pregnant and postpartum women. Context-specific, innovative, and multilevel system interventions are required at national, district, health facility, community and individual levels to scale up and sustain the lifelong antiretroviral therapy strategy among pregnant and breastfeeding women.

Introduction

Adoption of lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women living with HIV regardless of CD4 count or clinical stage (Option B+) for prevention of mother-to-child transmission (PMTCT) of HIV started in Malawi in 2011 [1]. Subsequently, this strategy was adopted by many countries in sub-Saharan Africa (SSA), including Uganda [24]. At that time, this choice was based on programmatic and operational reasons, particularly in generalized epidemics where there are high fertility rates, small birth intervals, poor access to CD4 testing, and a long duration of breastfeeding [5]. Evidence suggests that initiating ART in all pregnant and breastfeeding women would reduce HIV incidence and prevent HIV transmission in both current and future pregnancies [5].

Uganda adopted the lifelong ART strategy for pregnant and breastfeeding women in September 2012. By August 2013, the strategy had been scaled up in all the 112 districts across the country [6]. Moreover, Uganda started implementing the HIV “test and treat” policy for all children, pregnant and breastfeeding women, HIV-positive people with both TB or Hepatitis B co-infection and the HIV positive individuals in sero-discordant relationships in 2014 [7]. Besides, in the same year, Uganda adopted the World Health Organization’s recommendation for routine viral load testing as the standard of care compared to CD4 count for monitoring ART effectiveness [8]. However, in 2016, Uganda revised her “Consolidated guidelines for the prevention and treatment of HIV and AIDS” to include all adolescents and adults living with HIV on the “test and treat” policy. This policy involves providing lifelong ART to people living with HIV irrespective of CD4 count or World Health Organization (WHO) clinical stage [9]. These changes drastically increased the number of people living with HIV (PLHIV) who were initiated on ART which could end up constraining the health system [10]. Finally, in 2020, the Uganda Ministry of Health (MOH) rolled out revised HIV and AIDS prevention, and treatment guidelines which recommend the optimization of ART using Dolutegravir-based regimens as the preferred first line for all eligible PLHIV including pregnant and breastfeeding adolescent girls and women [11]. Typically, pregnant and lactating women are categorized under priority populations since they have a higher chance of acquiring or transmitting HIV. Besides, HIV-infected pregnant and postpartum women have unique needs including access to and utilization of HIV services, retention in care and adherence [12, 13]. Consequently, the WHO anticipated that additional support would be required to ensure optimal adherence and retention in HIV care for HIV positive women initiating lifelong ART since many would still be healthy [5]. As a result, mother-to-child transmission (MTCT) of HIV rate would rapidly abate. Although the MTCT rates in Uganda have declined over time, the desired level has not been achieved. For instance, a recent (2017–2019) impact evaluation study found that the overall MTCT rate in Uganda at 18 months post-delivery was 2.8% (95% CI: 2.0–3.9) [14] while an annual performance report showed that an estimated 5,300 MTCT infections occurred in the 2020/21 financial year [15]. Ergo, Uganda still lags behind in attaining the validation status for elimination of mother to child transmission (e-MTCT) of HIV.

To maximise the benefits of lifelong ART among pregnant and breastfeeding women, there is thus a need for a fully functional and organized health system to support the women and their infants. However, some studies have identified health system challenges in PMTCT implementation. Some of the challenges include; patient and health system difficulties such as poor communication and coordination among health system actors, poor clinical practices, and gaps in provider training [12]. A study conducted in Kenya identified insufficient training, staff and drug shortages, long queues, limited space and lack of patient-friendly services as some of the facility challenges in implementing lifelong ART among women on lifelong ART [16]. Although certain strategies have been implemented to address some of these challenges, a number of challenges such as antiretroviral drug (ARV) stock-outs, long distances to health facilities, low male partner involvement, and non-retention in care persist [1719]. Relatedly, a review conducted to assess progress, gaps and research needs towards achieving UNAIDS targets for pregnant and postpartum women in SSA identified a number of research priorities which included; barriers to ART uptake, retention in care, and sustained ART adherence [20].

There is therefore a need for contextual studies to explore the challenges and countermeasures to inform policy and programmatic improvements. To that effect, this study aimed at exploring the health providers’ perspectives of challenges along with the corresponding countermeasures to inform implementation of lifelong ART among HIV positive pregnant and breastfeeding women in central Uganda. Countermeasures are strategies that were used to overcome the challenges. Understanding the challenges and countermeasures in implementation of lifelong ART is critical to the success of the PMTCT of HIV program. The findings have potential to strengthen PMTCT programs to attain validation status for, achieve, and sustain e-MTCT of HIV and consequently contribute to the goal of ending AIDS as a public health threat by 2030 [21, 22]. The results are also relevant for similar contexts and in countries that are still experiencing similar challenges in implementing the current policy of test and treat [3, 2325].

Methods

Study design

A qualitative descriptive study was conducted among PMTCT services providers to elicit information on work challenges and countermeasures experienced during implementation of lifelong ART among HIV positive pregnant and breastfeeding women in central Uganda.

Study sites

The study was conducted in six public health facilities from three largely rural districts. The study sites were: Katikamu Health Centre (HC) III and Luwero HC IV in Luwero district; Mityana General Hospital (GH) in Mityana district; Ssunga HC III, Kyanamukaka HC IV and Masaka Regional Referral Hospital (RRH) in Masaka district. These districts and facilities were selected because they were among the first to implement lifelong ART strategy in Uganda and had fully operational PMTCT programs. The facilities could thus give comprehensive information on challenges and countermeasures. HIV positive pregnant, in labour, or post-delivery women accessed PMTCT services at the antenatal care (ANC), labour wards and postnatal care (PNC) clinics respectively.

Study population

Fifty-four participants took part in the study as key informants. They were grouped into formal and informal health providers. Formal providers were health workers who had received recognized training with a defined curriculum. They comprised midwives, nurses, counselors, nursing assistants, store assistants (Assistant inventory management officer), dispensers, laboratory assistants, clinical officers, and medical doctors. Informal health providers were health workers who had not received formally recognized training and typically not mandated by any formal institution. Instead, they had some level of training through apprenticeships, seminars, and workshops [26]. Informal providers enrolled in the study were expert clients. Expert clients are people living with HIV who have disclosed their HIV status and are willing to support other HIV clients voluntarily. We included participants who had been involved in lifelong ART services provision to pregnant or breastfeeding women for at least one year. Eligible participants who were too sick or unavailable at the time of the interviews to participate in the study were excluded from the study.

Selection of study participants

Participants (health providers) were purposively selected based on their roles, workstation, and experience. The aim was to select participants from a broad and diverse sample of providers and clinics to get a comprehensive view on experiences and the organization of services concerning implementing lifelong ART. In total, 54 study participants were included.

This study was part of a larger study on implementation of lifelong ART among HIV positive pregnant and breastfeeding women in Uganda. The objectives of the larger study were to determine the uptake of ART and other PMTCT related services by HIV+ pregnant women and their infants, and to assess retention in care and adherence to ART treatment. Concisely, the larger study enrolled 54 health providers, and 57 HIV positive women for qualitative descriptive inquiry [27, 28]. In addition, we recruited 507 HIV positive pregnant women who were prospectively followed during pregnancy, labour, after delivery and during breastfeeding for a total of 18 months to collect quantitative data [29, 30]. In the current manuscript, we analyse data from the 54 health providers to explore providers’ perspectives on the challenges encountered and countermeasures while implementing the PMTCT program.

Data collection

Data were collected between April and May 2014 using a key informant interview guide. The guide was developed to explore challenges and countermeasures experienced during implementation of lifelong ART among HIV positive pregnant and breastfeeding women. The semi-structured interview guide explored health providers’ experiences about challenges in provision of lifelong ART for HIV positive pregnant and breastfeeding women. Besides, countermeasures to deal with these challenges were explored. Table 1 shows the topics, questions and probes that were included in the study tool. The initial tool was pretested by some of the investigators and later discussed by the entire study team. We noted the consensuses and incongruities which we resolved through agreement. This ensured consistency in administration of the semi-structured key informant interview (KII) guide and interpretation of the questions. One-on-one interviews were conducted by four of the lead investigators (A.M., R.W., E.B., and R.N.). Each interview was audio-recorded with consent from the study participant and generally lasted 1.5 hours.

Table 1. Topics, questions and probes that were included in the study tool.

Topic Questions Probes
Challenges faced in supporting women on lifelong ART What challenges do you face in supporting women on lifelong ART? •Support for retention, adherence.
•Drug stock-outs, staffing numbers, and trainings/skills
Early infant diagnosis (EID) of HIV
challenges faced by pregnant women on Option B+ In your experience, what challenges do pregnant women on lifelong ART face? • Loss to follow up, ART adherence, keeping clinic appointments, drug stock-outs.
• Stigma, discrimination
• Referrals across difference service points such as ANC and ART clinics.
Countermeasures to address the challenges What measures has the health facility/clinic instituted to address the challenges and how effective are these strategies? • Support for retention, adherence.
• Drug stock-outs, staffing numbers and trainings/skills
• EID
• Loss to follow up, ART adherence, keeping clinic appointments.
• Stigma, discrimination
• Referrals across difference service points such as ANC and ART.

Data management and analysis

All audio-recorded data were transcribed verbatim; data in Luganda (local language) were concomitantly translated and transcribed into English. Final transcripts were stored securely on password-protected external drives. Data analysis was done using thematic analysis [31] and comprised the following steps: familiarisation with the data by reading through all the data repeatedly to understand the data. A list of ideas from the data was generated, and this was used to develop codes for analysis which A.M., H.B., and R.W. later discussed, unified and organized around challenges and countermeasures in implementation of lifelong ART among pregnant and breastfeeding women. All transcripts were exported to Atlas software (Atlas.ti, Version 7 software, Berlin, Germany) to guide the coding process. Eventually, the codes were sorted into subthemes, categories, and themes. Analysis was undertaken by A.M., H.B., and R.W. regularly evaluated and discussed the entire process of analysis and output for quality control and to ensure that the interpretation was close to the content and supported reflexivity. Illustrative quotations have been presented to enhance the study findings.

Ethical considerations

Makerere University School of Public Health Higher Degrees, Research and Ethics Committee and the Uganda National Council for Science and Technology approved the study. Permission was also obtained from the study districts and facilities. Participants were assured of anonymity and confidentiality: interviews were conducted in a private environment and transcripts did not bear participant names, nor any other identifiable details. Written informed consent was obtained from each study participant. The informed consent included a section on publication of anonymized responses. Each participant received compensation of 10,000 Uganda Shillings (equivalent to 4USD at the time of the study) for their time.

Results

Characteristics of study participants

Table 2 shows the characteristics of health providers who participated in the study. Overall, 54 interviews were conducted with 22 midwives, 8 nursing assistants, 7 expert clients, 4 doctors, 4 store assistants, 3 clinical officers, 3 nurses, one counsellor, one dispenser and one laboratory assistant. Majority of the participants were female (76%, 41/54), while half had received training in provision of lifelong ART to pregnant and breastfeeding women. Participants had worked in HIV care for a median (IQR) of 5 (1–8) years.

Table 2. Characteristics of study participants (n = 54).

Characteristic Number (%)
District
Masaka 34 (63.0)
Mityana 10 (18.5)
Luwero 10 (18.5)
Health Facility
Masaka RRH 12 (22.2)
Mityana GH 10 (18.5)
Kyanamukaka HC IV 10 (18.5)
Luwero HC IV 10 (18.5)
Katikamu HC III 7 (13.0)
Ssunga HC III 5 (9.3)
Sex
Female 41 (75.9)
Male 13 (24.1)
Cadre
Midwife 22 (40.7)
Nursing assistant 8 (14.8)
Expert client 7 (13.0)
Doctor 4 (7.4)
Store assistant 4 (7.4)
Clinical officer 3 (5.5)
Nurse 3 (5.5)
Counsellor 1 (1.9)
Dispenser 1 (1.9)
Laboratory assistant 1 (1.9)

Providers’ perspectives of challenges and countermeasures

The challenges are arranged under three themes of; inadequacy of HIV service delivery, non-utilization of HIV services, and suboptimal treatment adherence. Under each theme; categories, sub-themes, and countermeasures are presented as shown in Fig 1.

Fig 1. Illustrates the themes, categories, sub-themes, and countermeasures in implementation of lifelong ART services for PMTCT in three districts of Central Uganda.

Fig 1

1. Inadequacy of HIV service delivery and countermeasures

Two categories were identified under this theme: health worker-related; and logistics, and infrastructure-related.

a) Health worker-related. Four sub-themes were identified under this category.

Lack of relevant training

Half of the participants had not received training in the provision of ART for pregnant and breastfeeding women. Additionally, most interviewees reported a complete lack of training or lack of refresher training in lifelong ART provision among their colleagues. Among those directly involved in providing maternal, neonatal, and child health services; most of those who had not been trained were new at the facility. Participants also mentioned that, providers who were not directly involved in providing maternal, neonatal and child health services lacked relevant PMTCT training. These included laboratory, pharmacy and store staff.

“As a supplies officer [Store assistant], I was left out when trainings on lifelong ART for HIV positive pregnant and breastfeeding women were going on. They brought these drugs and they just told me that these are lifelong ARVs” Health Provider, Hospital.

All participants underscored the importance of training more providers to build capacity for sustainable lifelong ART service provision. To address the training gaps, study participants mentioned several strategies that were being used to build provider capacity. These included: on-job training, continuous medical education (CME), and supervision and mentorship by the MOH, district health officials, and implementing partners including Mildmay Uganda and Protecting Families Against HIV/AIDS. Supervision and mentorship were being done once every three months.

“Supervision and mentorship are conducted quarterly [once in three months]. The ideal would have been every month but due to resource constraints, this is not possible” Health Provider, HCIV

Shortage of health providers and heavy workload

Some participants highlighted that there were low numbers of some providers such as counsellors and clinical officers. In those cases, midwives were overloaded as they were expected to provide counselling, and maternal, neonatal, child and health services to many female clients and their children. The clinical workload was exasperated by the numerous PMTCT paperwork. The ensuant long queues affected staff attitudes who at times became flustered, and exhausted. Eventually, clients would experience delays at clinics.

“There are usually many clients [HIV positive individuals] yet we have very few health workers. We may have just three health workers and as one is immunizing the babies, one may be filling various cards and registers while the other is examining the pregnant women and at the same time checking their cards. …… the queue may be so long and there is no way she can talk to one lady for so long” Health Provider, Hospital.

Participants noted that health facilities adopted task-shifting using expert clients and village health team members (VHTs), to overcome staff shortages and heavy workload. Task shifting was observed as being very helpful in reducing the heavy workload and patient waiting time.

“We have expert clients who are also peer mothers in the ANC clinic. They help to counsel these mothers and to follow them up. They support us a lot in caring for the mothers on lifelong ART” Health Provider, HC IV.

Inadequate counselling

All participants highlighted the importance of adequate and quality counselling to ensure lifelong ART uptake, adherence and retention in care by the women and their infants. However, many felt that the counselling offered was inadequate due to a lack of counselling training, a shortage of dedicated counsellors, and limited time to counsel women on the range of issues, amidst an overwhelming number of women who required the service.

“Counselling is not enough; the workload is too much and the counsellors are very few yet, we have bigger clinics, the PMTCT and the ART clinics. I think we have about two counsellors and the other health workers provide the counselling but it is not really conducted satisfactorily. If we don’t give the mothers continuous information, they will become reluctant. Health Provider, Hospital.

Inadequate counselling was addressed through offering continuous (ongoing) counselling to women at every facility visit with emphasis on issues at hand.

“We offer ongoing counselling to HIV positive pregnant and breastfeeding mothers on lifelong ART every time they come back. We ask them the challenges they have met when they are at home taking the lifelong ART and then offer appropriate support. Health Provider, HC IV.

b) Logistics, and infrastructure-related. Under this category, six sub-themes were identified.

Limited space

Limited space was a prominent challenge cited by most participants. This was mostly attributed to the increased number of women seeking services, yet different services that had been integrated into the clinic were still offered in the same space. This resulted in congestion, which compromised privacy and confidentiality. Mothers were reportedly uncomfortable receiving services in such an environment.

“The place where they get the information is open and small, near a walk-way and there are so many activities taking place, it is extremely small. So, there are so many things that might divert their attention [when counselling is going on], we don’t have any privacy” Health Provider, Hospital.

Limited space, especially for counselling was difficult to address because it was affecting all other departments and not only limited to maternal, neonatal, and child health clinics. Providers said that they continued to work in the available space but wished that government and implementing partners would set up new buildings or temporary structures like tents.

Lack of guidelines

Most participants noted that copies of PMTCT guidelines were limited. In some facilities, participants reported never seeing any lifelong ART guidelines for pregnant and breastfeeding women. Where guidelines existed, health providers kept them in their consultation rooms and shared them when need arose.

Lack of information, education and communication (IEC) materials

PMTCT IEC materials were also lacking except for a few facilities that had such information on the walls.

“Yeah, there are some posters, but they are extremely few. I have seen one, but recently, they repainted the walls and I don’t know if they have put them up again” Health Provider, Hospital.

Additionally, participants noted that facilities lacked fliers and information packs that could be provided to mothers. A few participants felt these materials could be taken home by the women to assist their understanding and to enable them share with family members especially their spouses.

“It would be good to give HIV positive mothers materials such as leaflets with lifelong ART information because it reminds the woman to take the ARVs. Additionally, if put on the table—and my husband doesn’t know that am HIV positive; when my he comes and reads it, he will get the information and will realize that there is need to test for HIV” Health Provider, HC IV.

Lack of real-time electronic data capture system

In all the health facilities, participants highlighted that lack of real-time electronic data capture system was a challenge. They reported that they recorded patients’ data in PMTCT registers and on cards which were later given to staff in the records’ section for entry. Participants emphasized that time from data capture to electronic entry depended on the volume of patients and number of record assistants available. Once the data had been electronically entered it was used to track mothers and later their babies as well.

“We record the mother’s information on paper. Thereafter, we send it to the in-charge who verifies the information captured and then takes it to the records assistants for entry into the computer”. Health Provider, HC III

Insufficient funds

Many participants indicated that limited funding hindered making of phone calls, home visits and community out reaches to follow up women and their infants who missed clinic appointments.

Follow-up and tracking of women and their exposed infants require funds for transport. We at times use bicycles but they are few and some places are far away. I wish the Ministry of Health comes to provide more funds, bicycles, and motorcycles”. Health Provider Hospital

Participants said that in addition to use of VHTs and expert clients, other strategies like health facility providers using facility and district vehicles, follow-up and track women despite the limited funding.

“We give the HIV positive women addresses of the VHTs to go and follow-up on them. The VHTs go to check whether the mother and baby are still there and why they are not coming for their clinic visits or taking the ART” Health Provider, Hospital

Stock-outs of HIV test kits, Cotrimoxazole and Nevirapine syrups

Most participants observed that health facilities occasionally faced shortage of HIV testing kits, Nevirapine and Cotrimoxazole syrups. However, it was acknowledged that at one point the shortage of testing kits was a country-wide challenge. Participants admitted that sometimes stock-outs were due to poor forecasting which was rectified by devising a mechanism for enhanced forecasting.

“We have been experiencing stock-outs for; testing kits and the syrup—baby syrup [meaning Nevirapine]”. Health Provider, HC IV

Internal re-allocation of supplies and borrowing from nearby facilities were used to address this, and at other times, dividing of drugs was done.

“We would request Nevirapine syrup from the lower-level health units which are not very busy……It reached a moment where we had to share the Nevirapine syrup among two babies”. Health Provider, Hospital

In cases where providers were completely constrained, they would inform the implementing partners who would then bring the logistics.

2. Non-utilization of HIV services and countermeasures

Two categories are presented: HIV-related stigma and accessibility related.

a) HIV-related stigma. Four sub-themes are presented under this category.

Non-disclosure of HIV positive status

All study participants expressed that non-disclosure of HIV positive status was a significant and common challenge. They highlighted that many HIV-positive women feared disclosing their HIV status and the women perceived it that they would be stigmatized. It was noted that some women didn’t disclose their HIV positive status to their partners since they weren’t sure of their spouses’ reaction to the HIV+ result. Of most concern to the women, was fear of negative impact on relationships.

“The man [spouse] will chase me away or run away from me, yet this is still a new marriage! Health Provider, Hospital.

“She will then tell you, ‘ah’! Musawo [health worker] leave me alone, what if I tell him [spouse] and he tells me that am the one who brought the virus!” Another one will say, “what if he [spouse] chases me away with my child……. just leave me alone”. Actually, most of them do not tell them [spouses] about their HIV positive status and being on ART” Health Provider, Hospital.

The women ended up hiding their ARVs, missing appointments and not adhering to ART.

“The first challenge is non-disclosure of HIV positive status! Mothers were initiated on lifelong ART during ANC and post-delivery, but even after all the counselling is done, some mothers refuse to disclose the positive HIV status to their partners. This mother’s ART adherence may be affected because she may not be able to take the drugs when the husband is around. Secondly, she may fear to keep the drugs with her in the house” Health Provider, HC IV.

Denial of HIV positive results

During interviews, many participants reported that some women did not believe they were HIV-positive. Such women reportedly repeated the test at other facilities which delayed ART initiation.

“One woman said that she has been delivering all her children normally [meaning children who were HIV negative] and now we are telling her that she is HIV-positive? How comes? In other words, she doubted her HIV status” Health Provider HC III.

Fear to be followed up

Participants noted that some women did not welcome being visited or followed up in the communities where they lived due to HIV-related stigma with some providing incorrect addresses and/or telephone numbers. Sometimes women switched off their phones. This affected follow-up and linkage to HIV community-based services.

“Yes, we try to call them, but it is hard to find them. When they get to know your telephone contact, they stop picking your calls! Sometimes, when you call them [women], they will tell you that they are busy. Others may tell you that they shifted to another place for the same services” Health Provider HC IV

Participants said that the use of ongoing counselling, expert clients and VHT support were the strategies in place to overcome non-disclosure, and denial of HIV positive results, and fear to be followed-up.

Unwillingness to be linked to other intra-facility service care points

There are established mechanisms to link women and their infants to different intra-facility service care points, however, several challenges were cited by study participants. For example, some women were unwilling to be linked for intra-facility HIV services mainly because of HIV–related stigma. Many participants reported that some women feared being seen in general HIV clinics by relatives, friends and or neighbours.

“After giving birth, the mothers are supposed to attend the EID and general HIV clinics from the other side and there are many other patients seated together there. So, some fear and are unwilling to be linked to those other clinics. They prefer to stay at the PNC clinic where they are few and receive the clinic services quickly”. Health Provider, Hospital.

To overcome this challenge providers cited various strategies. The time of follow-up within the PNC was extended at several facilities to address this lack of willingness to transfer to general HIV chronic care clinics. In four of the six facilities, women were staying in the PNC beyond the recommended six weeks after giving birth.

“Actually, we continue keeping them within the PNC clinic until the women are ready for referral/linkage to the ART clinic successfully before they deliver or after they have delivered” Health Provider, HC IV.

As another strategy, women were accompanied by either a midwife, a counsellor, an expert client, or a VHT member from one service point to another, to ensure successful linkage. For example, women would be accompanied from the ANC clinic to the infant immunization clinics or to the EID testing care point and general HIV clinic.

“Mothers who come here for their first time don’t know us or the different health service care points. I move with the mother showing her around and what is done until we reach the EID care point. There is a person responsible for EID, and then I introduce that medical worker to the mother” Health Provider, HC IV.

b) Accessibility related. Under this category, two sub-themes were identified. These were:

Large catchment areas

Some participants reported that they serve women who came from distant places to the study facilities. Facilities especially in rural areas that were close to the women didn’t offer lifelong ART services.

Lack of transport

Most HIV-positive pregnant women could not afford transport costs which impacted their ability to attend appointments.

Some women come from very far! They stay like 20 miles away from here. Such women have a challenge of transport coming here every month. Health Provider HC IV.

To address accessibility-related challenges study participants noted that they used outreaches during which women on lifelong ART would be clinically evaluated and appropriately treated. Additionally, community members were engaged in health education and, HIV counselling and testing (HCT) which was envisaged to reduce community-related-HIV stigma. Besides, expert clients and VHTs would support the women to cope with the lifelong ART.

“We have three outreaches in a month. We have a number of landing sites where we conduct outreaches. We have our “Kizindalo” [big loud speaker] that we use to call and mobilize them. When they come, we counsel and test them. Those who test HIV positive, are counselled and enrolled into care, while those who test negative are only counselled. We use the occasion to reduce stigma tendencies through health education” Health Provider, HC IV.

However, it was noted that outreaches were expensive and time-consuming which calls for more resources and consequently result in sustainability challenges.

Furthermore, some participants reported that some female clients were given additional ARV supplies to reduce visits to clinics for collection of medication. This was anticipated to reduce on the transport costs.

“Some women who come from far are given ARVs for two months instead of one to reduce on the frequency of their clinic appointments. In addition, we have been provided with some fuel to take the ARVs and do HIV testing to the community through outreaches”. Health Provider, Hospital.

3. Suboptimal treatment adherence and countermeasures

The categories under this theme were ART-related, and male spouse related.

a) ART-related. Two sub-themes are presented.

Fear of ART side effects

Most participants said that many women feared ART side effects, and some of which were reported to have been grave.

“She [HIV positive mother] refused ARVs claiming that she will get a skin rash or even die. At least, she would take Septrin [Cotrimoxazole] but not ART]. She [HIV positive mother] tells you that some of her relatives suffered from HIV and when they started taking ARVs, they got severe side effects and some actually passed away” Health Provider, HC III.

Preference for traditional medicines

Several study participants mentioned that some women would stop using ART and opt to use local herbs with a misconception that they would treat HIV as illustrated by the quote below;

“Some women stop taking their HIV drugs and resort ‘budomola’ meaning the local herbs used to treat HIV. Such mothers continue taking those herbs. But for us [health providers] here, we don’t support them to use those herbs because when they will give birth to HIV positive babies in the long run”. Health Provider, HC III

Participants emphasized that fear of ART side effects and preference for traditional medicines were addressed using similar strategies. These included health education, continuous group and individual counselling, and formation of family support groups (FSGs).

Participants noted that FSGs had helped significantly in addressing these challenges through peer support.

“Family support groups are helpful; when one is HIV positive, alone and gets a problem, it disturbs a lot but when one is in a group and another person mentions the very problem you are encountering, then you will realize that you are not alone. As a result, your mind is settled” Health Provider, HC III.

b) Male spouse related. Low male partner involvement in care was identified as the subtheme under this category.

Low male partner involvement in care

Low male partner involvement in care was a common finding. Participants noted that some women would even bring different men other than their partners whenever they are told to bring their spouses. This was attributed to fear for consequences of HIV positive status disclosure.

“We tell the women to come with their husbands for HIV counselling and testing, and treatment but majority don’t want. The mothers tell you that the men are busy while others are scared to come to health facilities”. Health Provider, HC III.

Some men were reported to be unsupportive during ANC, delivery and PNC. Partner support related challenges intensified after delivery especially when the woman did not disclose her HIV status.

“We have very few husbands that accompany pregnant women and my fear is that when one doesn’t have a treatment partner, there is nobody to share with the challenges they are facing. If the man is not involved, what will happen if that woman depends on the man for financial support? At first, it was the pregnancy driving the man to give money to the pregnant mother to come for ANC, now that the baby has been delivered, what will be the reason for the husband to give transport to this mother to come for ART? Health Provider, Hospital.

There were various interventions across facilities to overcome low male involvement. In most facilities, women who came with their husbands were prioritized for health services. However, in other instances, men would actively be involved in the care that the wives received.

“Apart from health education that we provide, the men are there with us, when we are taking body weight and blood pressure; we also take theirs (the men). Inside the examination room, we also ask the husband if he is having any sickness and we give them the treatment. Moreover, after I examine the mother, I ask the spouse, [have you ever felt your baby’s heart beating from the uterus?] Then the person says no. Then I ask, “Do you wish to feel it beating?” When he agrees, I just put a foetal scope there, call him and give him instructions. When the husband hears the baby’s heart beating, you see that he is really excited” Health Provider, HC IV.

Participants reported providing health services to men such as health education, screening for, and treating common illnesses motivated the men to accompany their wives to the health facilities. In other facilities, study participants said that they didn’t prioritize those who came as couples but thanked and recognized men who had accompanied their wives. Other strategies to improve male involvement encompassed community outreach, continuous counselling, health education, use of FSGs and peer fathers/male champions.

“We realized that some of the strategies that we are using motivate men to come with their spouses for lifelong ART services. The strategies include giving health education on topics like HIV, care for pregnant and breastfeeding women, medical male circumcision, sexually transmitted infections (STIs) and non-communicable diseases. Other approaches that we use are offering men health services such as screening for STIs, non-communicable diseases like hypertension and diabetes mellitus”. Health Provider, Hospital.

One participant said that they were exploring the possibility of encouraging men to be involved in care for their spouses. He suggested that they were going to target men when they come to visit their wives in the health facility which is common in the first few hours after delivery. This would be an opportunity to encourage male involvement since most men come to check on their wives and the new-born infants.

“Normally when the woman delivers, that is when her husband comes to see or pick her and the new-born. So, we are making an attempt to see whether we can use that as a time to counsel men as well. It is an opportunity that we have, to talk to the men” Health Provider, HC IV.

Discussion

This study explored challenges and countermeasures in the implementation of lifelong ART for pregnant and breastfeeding women from the health providers’ perspective in three districts in Central Uganda. Major challenges were: a lack of in-service and/or refresher training on lifelong ART, shortage of health providers, inadequate counselling, lack of real-time electronic data capture system, and stock-outs of HIV test kits, Nevirapine syrup and Cotrimoxazole syrups which might result in inadequate lifelong ART service delivery. Other major challenges such as non-disclosure of HIV positive status, fear to be followed up, large catchment area, and lack of transport suggest non-utilization of lifelong ART services. While challenges like fear of ART side effects, and low partner involvement in care could lead to suboptimal treatment adherence lifelong ART among pregnant and postpartum women.

Several strategies were being used and proposed to address the identified challenges. These included on-job training, continuous medical education, task shifting, ongoing counselling, FSGs, re-allocation of HIV commodities, use of peers, and conducting community outreaches.

The Uganda MOH working with U.S. President’s Emergency Plan For AIDS Relief (PEPFAR) and implementing partners have addressed some of the challenges such as training inadequacies, stock-outs, retention in care challenges, and staff shortages to ensure that Uganda remains on track to achieve both the UNAIDS and national 95-95-95 targets. Strategies that were employed to address the gaps include increasing funding for ARV procurement and stock monitoring, supply chain reform improvement, human resource performance management, improving referral and linkage structures, use of short message services, phone calls, and home visits to track the lost women and HIV exposed infants, bring back mother and baby campaign, and supporting outreaches [19, 32, 33]. Recent reports indicate that several of these challenges still exist including inadequate number of health workers, increased workload, lack of training, insufficient supplies and commodities, suboptimal ART adherence, non-disclosure of positive HIV status, low retention in care rates and low male partner involvement in care [17, 3436]. Likewise, we earlier reported challenges around adherence and non-disclosure of HIV positive status from the clients’ perspective [27, 30]. Therefore, this study adds to existing literature on challenges in implementation of lifelong ART among pregnant and breastfeeding women from the heath providers’ perspective. The study also describes approaches that were used to address the challenges. Addressing these persistent challenges will fast track the achievement and sustainability of e-MTCT outcomes towards ending AIDS as a public health threat by 2030 [21, 22].

Lack of relevant training and inadequate counselling

Quality of e-MTCT services continues to experience some flaws which should be addressed [35]. Challenges that result in inadequate HIV service delivery might be contributors to low quality e-MTCT services. Many health providers had not received training on PMTCT lifelong ART service provision. This was mostly among providers who were new in the facilities and those who were not directly involved in offering lifelong ART services. On the other hand, some of the previously trained providers lacked refresher training. Congruent with our findings, a study conducted in India, found that some health providers lacked training on PMTCT services [18]. Other studies including a systematic review and another study done among health care providers at four health facilities in western Kenya revealed that the PMTCT training received by health providers was insufficient [12, 16, 37]. Furthermore, despite the adoption and implementation of the innovative differentiated service delivery (DSD) models for HIV services in Uganda in 2016, a study found that health workers in 600 out of 1,800 health facilities providing ART had not yet been trained in DSD delivery [36]. This suggests persistent gaps in HIV service delivery training in Uganda. Our study finding calls for e-MTCT training of more health providers and refresher trainings for those who were already trained. Innovative trainings such as web based, virtual and modular would be more appropriate and cost-effective since they reduce movements of health providers from their work stations. Additionally, the web based and virtual designs could be appropriate in the current context of COVID-19 pandemic.

Moreover, the trainings could be designed to address gaps in counselling that our study identified as one of the major challenges. Although adequate counselling was earlier reported to be the reason for the women to start swallowing ART on the same day it was prescribed [29], this might have targeted the newly diagnosed HIV pregnant women. The counselling inadequacies might be partially attributed to lack of or insufficient training on e-MTCT services, limited time for counselling, overwhelming numbers of individuals who require HIV services, and a lack of trained counsellors. Adequate counselling is essential especially in preparing pregnant and breastfeeding women for lifelong ART [38]. It prepares the women for the lifelong journey of ART. In contrast, inadequate counselling results in low utilization of PMTCT services [39] which would deter the achievement of e-MTCT of HIV. Most challenges identified such as the denial of HIV+ results, fear of ART side effects, fear to be followed up and non-disclosure HIV status can be solved using good counselling skills.

Shortage of health providers

Shortage of health providers was another challenge identified by this study. Staffing inadequacy in Uganda is not only a PMTCT challenge but rather cuts across various programs [40]. Notably, our study identified counsellors and clinical officers as some of the health providers who were inadequately staffed. Unfortunately, this shortage in the PMTCT program is worsened by the extensive patient and documentation load associated with HIV service provision [41]. Similar to our study, a validation study on the path to e-MTCT of HIV and Syphilis in Uganda (2010–2018) showed that at facility and district level, 50% (64) and 54% (32) respectively, had inadequate staff in both category and numbers offering PMTCT services [17]. Correspondingly, a study in Nigeria revealed a huge lack of doctors, nurses and midwives to available to deliver PMTCT services [23]. Task shifting using non-formal health providers such as expert clients (peer/mentor mothers and fathers), community linkage facilitators and VHTs has been adopted to address this challenge. However, the number of this cadre of health workers remains low [42]. Non-formal providers might have more time with women on lifelong ART because some of them live within the same communities. Expert clients have lived HIV experience, placing them in a better position to handle HIV-related stigma challenges. Nevertheless, the use of a mix of formal health workers, expert clients and other informal volunteer workers calls for more innovation to ensure delivery of quality services and sustainability [4345]. The MOH and implementing partners should ensure adequate training, supervision and mentorship of expert clients, linkage facilitators and VHTs to enable them work effectively.

Lack of real-time electronic information capture, guidelines, and IEC materials

Absence of real-time electronic data capture system and limited supply of PMTCT guidelines and communication materials was noted as a shortfall. This finding is similar to results from a study in Malawi where health workers reported lack of information technology infrastructure which resulted in use of paper-based methods of data capture and storage [46]. Paper-based data has limitations such as storage, unreadable, double work, time consuming, and errors during entry into the electronic medical record system, and difficulties in analyses [46, 47]. In India, it was found that real-time electronic data capture systems improve health provider work style, data capture, linkage across different clinics and overall satisfaction with PMTCT work [48, 49]. MOH in collaboration with the donors should strengthen scale up of electronic medical records to enable real-time data capture, easy and timely analysis to inform decision making. Additionally, more copies of PMTCT guidelines should be distributed to health facilities to enhance standardized practice. Participants felt that PMTCT communication materials would be useful in disseminating information to individuals, families and communities especially men who are reluctant to visit health facilities. Client IEC materials have the potential to reduce HIV related stigma and hence increase utilization of PMTCT of HIV services [50]. Appropriate, context specific and easy to understand client PMTCT IEC materials should be availed to health facilities and communities.

Stock-outs of HIV test kits, Nevirapine and Cotrimoxazole syrups

Our findings show occasional stock-outs of HIV test kits, Nevirapine and Cotrimoxazole syrups. This is consistent with findings from a study in India, where study participants reported shortages of HIV testing kits, and Nevirapine for infants [18]. However, a study from health facility surveys in six SSA countries had varied results. Stock-outs of HIV test kits and ARVs were common in Tanzanian health facilities [51]. Stock-outs might suggest poor forecasting, management, and monitoring of these essential HIV commodities. A lack of HIV testing kits, Nevirapine and Cotrimoxazole syrups is unacceptable. HIV testing is the entry point for primary and secondary prevention as well as care and treatment, while the ARVs supply chain is a major component of a systematic program for the prevention and treatment of HIV/AIDS [5254]. Health facilities with stock-outs would make arrangements to get these from facilities that had enough stock. This is in line with the MOH redistribution strategy [7]. Although the Uganda MOH with support from partners is closely undertaking ARV stock monitoring and management using the Web-Based ARV Ordering and Reporting System [19], these findings underscore the need for all e-MTCT of HIV stakeholders to work together to avert the recurrent stock-outs of HIV commodities. This could be done by strengthening the supply chain management capacity at national, regional, district and health facility levels which would ensure accurate and timely ordering and provision of appropriate real-time stock status data at health facilities.

Unwillingness to be referred

Health providers noted that some women refused to be referred to other HIV intra-facility service care points. The women preferred to remain in the antenatal clinic even after giving birth which was attributed to HIV- related stigma. This finding is similar to results from a study that was done in Nigeria. Participants reported that HIV positive women feared to get services from designated places in the health facilities [55]. Refusal to receive services from other HIV care points is likely to result in loss-to-follow up along the PMTCT cascade. Facilities used various approaches to ensure that women are not lost during the linkage process. Strategies used included accompanying women from one service point to another, following up referrals that were given to women and only referring women when they were ready. This was to ensure that women reach the point of referral. Howbeit, accompanying women could be a challenge and not feasible where health providers face staff shortages and heavy workload.

Large catchment area and lack of transport

Despite the target by the Uganda MOH that 85% of population to reside within a distance of 5km from a health facility, distance to health facilities remains a challenge [56, 57]. Our study highlights the challenge of large catchment areas and lack of transport. These findings concur with those from Ethiopia and South Africa where restricted physical access, and transportation to PMTCT sites were barriers to utilization of PMTCT services [58, 59]. Expert clients, linkage facilitators, VHTs and community outreaches were being employed to address this challenge. Nonetheless, these strategies are costly and unsustainable. Given that several women and other clients on test and treat attend HC IIIs and IIs for both ANC and immunization yet these facilities often lack comprehensive HIV services, the MOH ought to strengthen HIV services at HC IIIs, accredit large volume HC IIs to provide comprehensive HIV services.

Low male partner involvement in care

Men are the main decision-makers in a home especially in Africa [60, 61]. They thus influence women’s access to maternal, neonatal and child health services, and thus impacting their health outcomes [61]. Male involvement in implementation of the lifelong ART strategy affects uptake, adherence and retention in care [6264]. Low male partner involvement in care for lifelong ART among pregnant and breastfeeding women stood out in our study findings as a challenge. Consistent with our study, findings from studies conducted elsewhere show low male partner involvement in care [6567]. For example, in Mwanza region–Tanzania the study showed that only 24.7% of mothers indicated that their male partners were involved in PMTCT, whereas only 20.9% of men from a study in Ethiopia had a high involvement index in PMTCT services [66, 67].

Facilities in our study were engaging some strategies to improve male involvement in lifelong ART services but providers reported that the impact was limited possibly because they were still in infancy stages. Strategies include community sensitization of men about benefits of ANC and lifelong ART, having male friendly services for men who accompany their spouses and offering quality services. Strategies such as use of mentor fathers/champions, health education, community sensitizations and screening of non-communicable diseases for men might have a great potential to improve male involvement in lifelong ART services. Regrettably, male partner involvement has remained a gap in the PMTCT of HIV program [17]. The countermeasures that our study identified to address low male involvement could be implemented in other African country settings so as to accommodate male partners in attending, ANC, delivery, and PNC services with their female partners. Albeit, more innovations such as age and population specific dialogues are needed to overcome low male partner involvement in e-MTCT of HIV.

Strengths and limitations

A broad range of providers implementing the PMTCT program were interviewed which enabled us to explore challenges and countermeasures within the facilities. The data was collected in 2014 and some of the findings may not be applicable in the current context. In addition, the PMTCT program has gone through a number of transitions in the last decade. For example, the last transition is the change to Dolutegravir ART-based regimen [11]. Viral load monitoring has become the standard of care compared to CD4 count. These changes may have implications on our results. However, several of the findings remain relevant and can be transferred to other facilities and settings with Uganda and beyond. Use of key informant interviews might have resulted into social desirability bias but this was minimized by use of experienced data collectors, establishing of rapport, use of probes, and conducting regular research team meetings.

Conclusions and recommendations

The study identified persistent challenges that were negatively impacting HIV service delivery and use, and subsequently treatment adherence. A number of countermeasures were being used to address these challenges. We recommend that; providers including community support groups offering lifelong ART services to pregnant and postpartum women should receive regular training, supervision, and mentorship. Training on lifelong ART services should start during the pre-service period for all clinical students. Adequate personalized pre-ART and continuous counselling should be offered to HIV-positive pregnant and breastfeeding women. Facilities should be supported to ensure that they; are well stocked with lifelong ART and health supplies, and acquire real-time electronic data cap capture system. Ministry of health should scale-up the strategy of task shifting using peers, VHTs, and male champions, and consider accreditation of the large volume HC IIs and those in distant rural areas to provide e-MTCT services. Research to assess the effectiveness of the key countermeasures is recommended so as to inform adoption and scale up.

Acknowledgments

The authors wish to thank all study participants without whom this study wouldn’t have been successful. Special thanks also go to the respective heads of facility for Masaka RRH, Mityana General Hospital, Luwero HC IV, Kyanamukaka HC IV, Ssunga and Katikamu HC IIIs for their continued support rendered to us throughout the data collection process. We also acknowledge the tireless efforts of all study interviewers in collecting data at their respective study sites.

Abbreviations

A.M.

Aggrey David Mukose

E.B.

Esther Buregyeya

H.B.

Hilde Bastiaens

R.N

Rose Naigino

R.W.

Rhoda K. Wanyenze

Data Availability

Due to restrictions by the Makerere University School of Public Health Higher Degrees, Research and Ethics Committee, some access restrictions apply to the data for reasons of safety and protection of study subjects and their institutions. Sensitive qualitative data was collected from study participants and they didn’t consent to open data access. However, criteria eligible researchers with interest in the data may request for anonymized data access through the Chair Higher Degrees, Research and Ethics Committee (contact via sphrecadmin@musph.ac.ug and cc:jkagaayi@musph.ac.ug).

Funding Statement

This study was funded by the Global Fund through the Ministry of Health-Uganda [Grant Number: UGD-708-G07-H]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. The Lancet. 2011;378(9787):282–4. doi: 10.1016/S0140-6736(10)62303-3 [DOI] [PubMed] [Google Scholar]
  • 2.CDC. Impact of an innovative approach to prevent mother-to-child transmission of HIV—Malawi, July 2011-September 2012. Atlanta, Georgia, United States: Centers for Disease Control Prevention, 2013. 1545-861X Contract No.: 8. [PMC free article] [PubMed] [Google Scholar]
  • 3.Kalua T, Barr BAT, Van Oosterhout JJ, Mbori-Ngacha D, Schouten EJ, Gupta S, et al. Lessons learned from option B+ in the evolution toward “test and start” from Malawi, Cameroon, and the United Republic of Tanzania. Journal of acquired immune deficiency syndromes (1999). 2017;75(Suppl 1):S43. doi: 10.1097/QAI.0000000000001326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.NAC. National 2012 global AIDS response progress report: Malawi country report. Lilongwe, Malawi: The Malawi, National AIDS Commission, 2012. [Google Scholar]
  • 5.WHO. Consolidated Guidelines on the use of Antiretroviral drugs for Treating and Preventing HIV infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization, 2016. 978 92 4 154968 4. [PubMed] [Google Scholar]
  • 6.Godfrey E. PMTCT Implementation in Uganda: Option B Plus Experience 2013 [cited 2013]. Available from: http://www.vaccineenterprise.org/sites/default/files/02-Esiru_0.pdf.).
  • 7.MOH. Consolidated guidelines for prevention and treatment of HIV in Uganda. In: ACP, editor.: MOH; 2014. [Google Scholar]
  • 8.UAC. The Uganda HIV and AIDS Country Progress Report July 2015-June 2016. Kampala, Uganda: 2016 26 August 2016.
  • 9.MOH. Consolidated guidelines for prevention and treatment of HIV in Uganda. In: ACP, editor. Kampala, Uganda: MOH; 2016. p. 154. [Google Scholar]
  • 10.Mikkelsen E, Hontelez JAC, Jansen MPM, Bärnighausen T, Hauck K, Johansson KA, et al. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLOS Medicine. 2017;14(2):e1002240. doi: 10.1371/journal.pmed.1002240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.MOH. Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda 2020. Kampala, Uganda: MOH; 2020. p. 245. [Google Scholar]
  • 12.Colvin CJ, Konopka S, Chalker JC, Jonas E, Albertini J, Amzel A, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PloS one. 2014;9(10):e108150. doi: 10.1371/journal.pone.0108150 ; PubMed Central PMCID: PMC4193745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.UNAIDS. Women and HIV: a spotlight on adolescent girls and young women. 2019.
  • 14.MOH. Impact of the National Program for Prevention of Mother—to Child Transmission of HIV in Uganda, Evaluation Report 2017–2019. Kampala, Uganda: Ministry of Health, AIDS; 2022 January 2022.
  • 15.MOH. Annual Health Sector Performance Report Financial Year 2020/21. Kampala, Uganda: MOH; 2021. p. 156. [Google Scholar]
  • 16.Helova A, Akama E, Bukusi EA, Musoke P, Nalwa WZ, Odeny TA, et al. Health facility challenges to the provision of Option B+ in western Kenya: a qualitative study. Health policy and planning. 2017;32(2):283–91. doi: 10.1093/heapol/czw122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.MOH. Progress Report for Validation on the Path to Elimination of Mother to Child Transmission of HIV and Syphilis in Uganda (2010–2018). In: ACP, editor. Kampala, Uganda: MOH; 2019. p. 80. [Google Scholar]
  • 18.Suryavanshi N, Mave V, Kadam A, Kanade S, Sivalenka S, Kumar VS, et al. Challenges and opportunities for outreach workers in the Prevention of Mother to Child Transmission of HIV (PMTCT) program in India. PloS one. 2018;13(9):e0203425. doi: 10.1371/journal.pone.0203425 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.PEPFAR. PEPFAR Uganda Country Operational Plan (COP) 2019 Strategic Direction Summary April 12, 2019. Washington, DC, USA. 2019: PEPFAR, 2019.
  • 20.Abuogi LL, Humphrey JM, Mpody C, Yotebieng M, Murnane PM, Clouse K, et al. Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs. Journal of virus eradication. 2018;4:33–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.UAC. National HIV and AIDS Strategic Plan 2015/2016–2019/2020: An AIDS Free Uganda, My Responsibility! Uganda AIDS Commission, Republic of Uganda. Kampala, Uganda: Uganda AIDS Commission, 2015. 2015. [Google Scholar]
  • 22.UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2014. [Google Scholar]
  • 23.Olakunde BO, Adeyinka DA, Olawepo JO, Pharr JR, Ozigbu CE, Wakdok S, et al. Towards the elimination of mother-to-child transmission of HIV in Nigeria: a health system perspective of the achievements and challenges. International health. 2019;11(4):240–9. doi: 10.1093/inthealth/ihz018 [DOI] [PubMed] [Google Scholar]
  • 24.Etoori D, Kerschberger B, Staderini N, Ndlangamandla M, Nhlabatsi B, Jobanputra K, et al. Challenges and successes in the implementation of option B+ to prevent mother-to-child transmission of HIV in southern Swaziland. BMC Public Health. 2018;18(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gugsa S, Potter K, Tweya H, Phiri S, Sande O, Sikwese P, et al. Exploring factors associated with ART adherence and retention in care under Option B+ strategy in Malawi: A qualitative study. PloS one. 2017;12(6):e0179838. doi: 10.1371/journal.pone.0179838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sudhinaraset M, Ingram M, Lofthouse HK, Montagu D. What is the role of informal healthcare providers in developing countries? A systematic review. PloS one. 2013;8(2):e54978. doi: 10.1371/journal.pone.0054978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Buregyeya E, Naigino R, Mukose A, Makumbi F, Esiru G, Arinaitwe J, et al. Facilitators and barriers to uptake and adherence to lifelong antiretroviral therapy among HIV infected pregnant women in Uganda: a qualitative study. BMC pregnancy and childbirth. 2017;17(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mukose AD, Bastiaens H, Buregyeya E, Naigino R, Makumbi F, Musinguzi J, et al. Health Provider Perspectives of Health Facility Preparedness and Organization in Implementation of Option B+ among Pregnant and Lactating Women in Central Uganda: A Qualitative Study. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2019;18:2325958219833930. doi: 10.1177/2325958219833930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mukose AD, Bastiaens H, Makumbi F, Buregyeya E, Naigino R, Musinguzi J, et al. What influences uptake and early adherence to Option B+ (lifelong antiretroviral therapy among HIV positive pregnant and breastfeeding women) in Central Uganda? A mixed methods study. PloS one. 2021;16(5):e0251181. doi: 10.1371/journal.pone.0251181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Naigino R, Makumbi F, Mukose A, Buregyeya E, Arinaitwe J, Musinguzi J, et al. HIV status disclosure and associated outcomes among pregnant women enrolled in antiretroviral therapy in Uganda: a mixed methods study. Reproductive health. 2017;14(1):1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Braun V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3:77/101. [Google Scholar]
  • 32.MOH. Implementation Guide for Differentiated Service Delivery Models of HIV Services in Uganda. Kampala, Uganda: MOH, ACP; 2017. June 2017. [Google Scholar]
  • 33.PEPFAR. PEPFAR Uganda Country Operational Plan (COP) 2018 Strategic Direction Summary Washington, DC, USA. 2018: 2018 April 17, 2018.
  • 34.MOH. National Plan For Elimination of Mother-to-Child Transmission of HIV, Syphilis and Hepatitis B (2020/21–2023/24). 2020.
  • 35.MOH. Annual Health Sector Performance Report Financial Year 2019/20 Kampala, Uganda: MOH; 2020. [Google Scholar]
  • 36.Zakumumpa H, Rujumba J, Kwiringira J, Katureebe C, Spicer N. Understanding implementation barriers in the national scale-up of differentiated ART delivery in Uganda. BMC health services research. 2020;20(1):1–16. doi: 10.1186/s12913-020-5069-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. Journal of the International AIDS Society. 2013;16:18588. doi: 10.7448/IAS.16.1.18588 ; PubMed Central PMCID: PMC3717402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011;8(3):e1000422. doi: 10.1371/journal.pmed.1000422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hampanda K. Vertical Transmission of HIV in Sub-Saharan Africa: Applying Theoretical Frameworks to Understand Social Barriers to PMTCT. ISRN Infectious Diseases. 2013;2013:420361. doi: 10.5402/2013/420361 [DOI] [Google Scholar]
  • 40.Koutsoumpa M, Odedo R, Banda A, Meurs M, Hinlopen C, Kramer K, et al. Health workforce financing in Uganda: challenges and opportunities. European Journal of Public Health. 2020;30(Supplement_5). doi: 10.1093/eurpub/ckaa165.525 [DOI] [Google Scholar]
  • 41.Sande O, Burtscher D, Kathumba D, Tweya H, Phiri S, Gugsa S. Patient and nurse perspectives of a nurse-led community-based model of HIV care delivery in Malawi: a qualitative study. BMC public health. 2020;20:1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.CSOs. The People’s Voice Uganda: Community Priorities—PEPFAR Country Operational Plan 2020. CSOs, 2020. 2020. [Google Scholar]
  • 43.Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Human resources for health. 2010;8(1):8. doi: 10.1186/1478-4491-8-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Celletti F, Wright A, Palen J, Frehywot S, Markus A, Greenberg A, et al. Can the deployment of community health workers for the delivery of HIV services represent an effective and sustainable response to health workforce shortages? Results of a multicountry study. Aids. 2010;24:S45–S57. doi: 10.1097/01.aids.0000366082.68321.d6 [DOI] [PubMed] [Google Scholar]
  • 45.WHO. Serving the needs of key populations: Case examples of innovation and good practice on HIV prevention, diagnosis, treatment and care. 2017. 9241512539. [Google Scholar]
  • 46.Kumwenda W, Kunyenje G, Gama J, Chinkonde J, Martinson F, Hoffman I, et al. Information management in Malawi’s prevention of Mother-to-Child Transmission (PMTCT) Program: Health workers’ perspectives. Malawi Medical Journal. 2017;29(4):306–10. doi: 10.4314/mmj.v29i4.5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gourlay A, Wringe A, Todd J, Michael D, Reniers G, Urassa M, et al. Challenges with routine data sources for PMTCT programme monitoring in East Africa: insights from Tanzania. Global Health Action. 2015;8(1):29987. doi: 10.3402/gha.v8.29987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Suryavanshi N, Kadam A, Kanade S, Gupte N, Gupta A, Bollinger R, et al. Acceptability and feasibility of a behavioral and mobile health intervention (COMBIND) shown to increase uptake of prevention of mother to child transmission (PMTCT) care in India. BMC public health. 2020;20:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Thomas DSK, Bull S, Nyanza EC, Hampanda K, Liedtke M, Ngallaba SE. An mHealth pilot designed to increase the reach of prevention of mother-to-child transmission of HIV (PMTCT) across the treatment cascade in a resource-constrained setting in Tanzania. PloS one. 2019;14(2):e0212305. doi: 10.1371/journal.pone.0212305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.McDougal L, Moteetee MM, Mohai F, Mphale M, Mahanty B, Motaung B, et al. Lesotho’s Minimum PMTCT Package: lessons learned for combating vertical HIV transmission using co-packaged medicines. Journal of the International AIDS Society. 2012;15(2):17326. doi: 10.7448/IAS.15.2.17326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Church K, Machiyama K, Todd J, Njamwea B, Mwangome M, Hosegood V, et al. Identifying gaps in HIV service delivery across the diagnosis‐to‐treatment cascade: findings from health facility surveys in six sub‐Saharan countries. Journal of the International AIDS Society. 2017;20(1):21188. doi: 10.7448/IAS.20.1.21188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Altevogt BM, Wizemann TM, Norris SMP, Pankevich DE. Improving access to essential medicines for mental, neurological, and substance use disorders in sub-Saharan Africa: workshop summary: National Academies Press; 2014. [PubMed] [Google Scholar]
  • 53.Spisak C, Morgan L, Eichler R, Rosen J, Serumaga B, Wang A. Results-based financing in Mozambique’s central medical store: a review after 1 year. Global Health: Science and Practice. 2016;4(1):165–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Branson BM. The future of HIV testing. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2010;55:S102–S5. doi: 10.1097/QAI.0b013e3181fbca44 [DOI] [PubMed] [Google Scholar]
  • 55.Dirisu O, Eluwa G, Adams E, Torpey K, Shittu O, Adebajo S. "I think this is the only challenge… the stigma” Stakeholder perceptions about barriers to Antenatal care (ANC) and Prevention of mother-to-child transmission (PMTCT) uptake in Kano state, Nigeria. PloS one. 2020;15(4):e0232028. doi: 10.1371/journal.pone.0232028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.MOH. Health Sector Development Plan 2015/16–2019/20. Kampala, Uganda: MOH; 2015. p. 110. [Google Scholar]
  • 57.EPRC. Universal Health Coverage in Uganda: The critical health infrastructure, healthcare coverage and equity. Kampala, Uganda: EPRC, 2017. June 2017. [Google Scholar]
  • 58.Akal CG, Afework DT. Status of prevention of mother-to-child transmission (PMTCT) services utilization and factors affecting PMTCT service uptake by pregnant women attending antenatal care clinic in selected health facilities of Afar Regional State, Ethiopia. Journal of environmental and public health. 2018;2018. doi: 10.1155/2018/5127090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Habedi D. Healthcare workers’ perspectives on availability and accessibility of the prevention of mother-to-child-transmission programme in North West province, South Africa. African Journal of AIDS Research. 2020;19(1):24–33. doi: 10.2989/16085906.2019.1676803 [DOI] [PubMed] [Google Scholar]
  • 60.Mosha I, Ruben R, Kakoko D. Family planning decisions, perceptions and gender dynamics among couples in Mwanza, Tanzania: a qualitative study. BMC public health. 2013;13(1):1–13. doi: 10.1186/1471-2458-13-523 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Yargawa J, Leonardi-Bee J. Male involvement and maternal health outcomes: systematic review and meta-analysis. Journal of Epidemiology and Community Health. 2015;69(6):604–12. doi: 10.1136/jech-2014-204784 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Alemayehu M, Etana B, Fisseha G, Haileslassie K, Yebyo H. The role of male partner involvement on mother’s adherence to PMTCT care and support, Tigray, Northern Ethiopia. Fam Med Med Sci Res. 2014;3(04). [Google Scholar]
  • 63.Belato DT, Mekiso AB, Begashaw B. Male partners involvement in prevention of mother-to-child transmission of HIV services in Southern Central Ethiopia: in case of Lemo District, Hadiya Zone. AIDS research and treatment. 2017;2017. doi: 10.1155/2017/8617540 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Nyondo AL, Chimwaza AF, Muula AS. Exploring the relevance of male involvement in the prevention of mother to child transmission of HIV services in Blantyre, Malawi. BMC International Health and Human Rights. 2014;14(1):1–12. doi: 10.1186/s12914-014-0030-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Yah CS, Tambo E. Why is mother to child transmission (MTCT) of HIV a continual threat to new-borns in sub-Saharan Africa (SSA). Journal of infection and public health. 2019;12(2):213–23. doi: 10.1016/j.jiph.2018.10.008 [DOI] [PubMed] [Google Scholar]
  • 66.Elias M, Mmbaga EJ, Mohamed AA, Kishimba RS. Male partner involvement in the prevention of mother to child transmission of HIV infection in Mwanza Region, Tanzania. The Pan African Medical Journal. 2017;27. doi: 10.11604/pamj.2017.27.90.8901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Amano A, Musa A. Male involvement in PMTCT and associated factors among men whom their wives had ANC visit 12 months prior to the study in Gondar town, North west Ethiopia, December, 2014. Pan African Medical Journal. 2016;24(1). [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Desmond Kuupiel

25 Aug 2022

PONE-D-22-14861Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspectivePLOS ONE

Dear Dr. Mukose,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The comments can be found at the bottom of this letter.

Please submit your revised manuscript by Oct 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Desmond Kuupiel, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was funded by the Global Fund through Ministry of Health - Uganda; Grant Number: 683 UGD-708-G07-H. The contents of this article are solely the responsibility of the authors and do 684 not necessarily represent the official views of Global Fund, Ministry of Health or Makerere 685 University School of Public Health.”

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 “This study was funded by the Global

Fund through the Ministry of Health-Uganda [Grant

Number: UGD-708-G07-H]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Please respond to all the reviewers' comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Reviewer #1: The manuscript describes the challenges and countermeasures in the implementation of lifelong ART In central Uganda. The manuscript is very well written and easy to follow and understand. There are a couple of issues when addressed will further enrich the publication

1. Introduction: It will be useful if information on transmission rates of MTCT in Uganda is included in the overview. This will enable readers put the results in perspective

2. 54 providers from 6 facilities and 3 districts: kindly show in a table the number and categories of providers from each health facility

3. Even though, the authors acknowledge that data from 2014 may be an issue but think that the results may still be relevant. I am particularly concerned because MTCT has gone through a number transitions in the last decade. The last transition is the change to Dolutegravir with the attendant issues family planning particularly in the initial phase. In addition, viral load monitoring has become the standard of care compared to CD4 count. The implication of the results must be situated within the current context . This was not done

Reviewer #2: Thank you for this interesting manuscript. Please do a final editorial review after addressing the comments.

Abstract: Methods:

The authors note that there were 54 key informant interviews with providers from 6 facilities – in the manuscript, it seems that the key informants extend beyond providers, including for example expert clients (which is great for data quality) – please make this clear in abstract. Or is the term “provider” being used to include all these categories of informants?

Introduction:

Historical background to ART initiation in Uganda well documented, and rationale for manuscript well presented.

Methods:

Study sites: Do ethics requirements allow for facilities to be named? Double check study requirements regarding identifiers and protecting confidentiality of providers. Section on ethical consideration says they were assured of confidentiality.

Study population: See comment in abstract – It is a bit confusing who the participants in this study were – the authors say 54 key informant participants were included – and then lists them (Lines 129-131) – then later, Line 137, they say 54 health providers and 57 HIV positive women were enrolled. Are the initial 54 key informant participants the same as the 54 health providers? Please make this description clearer? In the results section, it is confirmed that the 54 key informants are as they are first listed in this section.

Thanks for clarifying what expert clients are. What are store assistants?

Line 133: Sentence starting “This study was part of…” – perhaps this should be the start of a new paragraph? Or clearly distinguish what is part of the study reported on in this manuscript, and what is the bigger study?

Lines 138-140: Once the details of the participants (all providers, or other key informants too) are clarified, make sure that this sentence outlining the aim of the manuscript is in line with this (provider’s perspective only?).

Data management and analysis (and elsewhere): Where author’s initials are used, standardise if they are written with periods/full stops or not (AM vs A.M).

Results:

Figure 1 quality is not very good – quite hard to read.

Countermeasures – are these only described when reported on? It would be helpful to highlight this, as under most challenges they are described, and others there is no mention of how providers deal with the challenges.

Descriptions in results – in some places these can be consolidated and summarised, as the illustrative quote gives the details – to double check that the summary point is not repetitive of what is reported in the quote (e.g. Lines 409-413: the countermeasure description could possibly be summarised as follows: “Participants reported that some clients were given additional ARV supplies to reduce visits to clinics for collection of medication” followed by the quote) – to check all.

Inadequacy of HIV service delivery and countermeasures:

Health worker related: Lack of relevant training:

Line 207: This quote is from a supplies officer, since the different categories of staff were interviewed, it may be helpful to specify in the quote identifier that it was a supplies officer at a hospital, not a health provider?

Are there any quotes/data to support the feedback of supervision and mentorship which were being done every 3 months? The limited training seems to indicate that not many people are exposed to this?

Shortage of health providers:

Line 219: Women – replace with female clients?

Line 220: Elaborate – how do long queues affect staff attitudes? Make them tired, flustered – this is linked closely to heavy workload. If too few staff, workload is more? Describe/distinguish the overlap between these points.

Logistics and infrastructure related: Lack of guidelines

It seems like the guidelines do exist, it is that there are a lack of hardcopies of these guidelines? This also links to training on guidelines – if people are aware of the guidelines, they only need to refer to hardcopies for points of clarification?

Insufficient funds:

What should the source of these funds be? Is it budget allowance from government?

Line 303-305: Who funds these activities if there is limited funding? NGOs? Individual healthcare providers?

Non-utilisation of HIV services and countermeasures:

HIV related stigma: Non-disclosure of HIV positive status

Line 333: perhaps reword – “fear of marriage breakages” to “fear of negative impact on relationships” – this extends to multiple partnerships scenarios, and the example given is about a marriage break-up.

Fear to be followed-up: Is this follow-up referring to treatment adherence follow-up, linkage to care, reminders to come for clinic visits, or what kind of follow up? It would be helpful to know what is being referred to here?

Unwillingness to be linked to other intra-facility service care points:

Line 367: What is EID? Make sure all acronyms in full first time.

Suboptimal treatment adherence and countermeasures:

ART related: Preference for herbs:

Should this section “preference for herbs” be reclassified as “preference for traditional medicines”? Is the use of herbs about using traditional medicines?

Male spouse related: Fear of spousal reaction:

This section seems to be very closely related to the section on stigma and non-disclosure – which was because of fear of spousal reaction, resulting in non-adherence? How were these themes differentiated? The link and distinction needs to be noted.

Low male partner involvement in care:

Lines 469-496: The countermeasures described here are really important, in many African country settings, these ANC and delivery services are not set up to accommodate male partners attending these services with their female partners. This can be highlighted in the discussion.

Discussion:

The authors note numerous really important recommendations throughout the discussion. Are there any considerations for how to take these recommendations forward – should there be government level strategizing, call for funding to increase budgets, further research, or how can these recommendations be implemented? (the last sentence of the conclusion section highlights research on the effectiveness of the countermeasures, which addresses this).

Fear of spousal reaction and low male partner involvement in care:

Line 640: Reference this first sentence.

Strengths and limitations:

To add that only “providers” were interviewed – client perspectives could have added value to the results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jan 20;18(1):e0280893. doi: 10.1371/journal.pone.0280893.r002

Author response to Decision Letter 0


12 Oct 2022

PONE-D-22-14861

Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspective.

Dear Academic Editor,

Thank you so much for all the comments and suggestions that were raised during the review process. We thank the reviewers for all the comments. They were very helpful and have enabled us to improve our manuscript.

We have addressed all comments in the “Point by point” response letter below. The changes are in track changes in the file labeled “Revised Manuscript with Track Changes”.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We have followed the PLOS ONE style requirements.

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was funded by the Global Fund through Ministry of Health - Uganda; Grant Number: 683 UGD-708-G07-H. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of Global Fund, Ministry of Health or Makerere University School of Public Health.”

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This study was funded by the Global Fund through the Ministry of Health-Uganda [Grant Number: UGD-708-G07-H]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

We have removed funding-related text from the manuscript. The Funding statement should remain as stated “This study was funded by the Global Fund through the Ministry of Health-Uganda [Grant Number: UGD-708-G07-H]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

We thank you so much Academic Editor for noting issues around data availability.

There are ethical or legal restrictions to sharing our qualitative data publicly.

Study participants were not consented to provide data access and the Higher Degrees, Research and Ethics Committee didn’t grant permission for data access. We have revised the data availability statement and provided the contact address for the Chair of the Higher Degrees, Research and Ethics Committee.

The contact information for the ethics committee is given below.

“The Chairperson Makerere University School of Public Health Higher Degrees, Research and Ethics Committee, P.O. Box 7072, Kampala. Telephone +256414 532207/543872/543437”

The data availability statement should now read as below:

“Due to restrictions by the Makerere University School of Public Health Higher Degrees, Research and Ethics Committee, some access restrictions apply to the data for reasons of safety and protection of study subjects and their institutions. Sensitive qualitative data was collected from study participants and they didn’t consent to open data access. However, criteria eligible researchers with interest in the data may request for anonymized data access through the Chair Higher Degrees, Research and Ethics Committee.”

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Review Comments to the Author

Reviewer #1: The manuscript describes the challenges and countermeasures in the implementation of lifelong ART In central Uganda. The manuscript is very well written and easy to follow and understand. There are a couple of issues when addressed will further enrich the publication

1. Introduction: It will be useful if information on transmission rates of MTCT in Uganda is included in the overview. This will enable readers put the results in perspective

We have included the information on transmission rates in the introduction section of the revised manuscript. Please see lines 87-91, on page 4.

2. 54 providers from 6 facilities and 3 districts: kindly show in a table the number and categories of providers from each health facility

A table showing characteristics including number and categories of providers has been included. This is labeled as Table 2 (Lines 235-237, on page 11). However, we have not provided a table with number and categories of providers from each facility. Providing such a table would inadvertently compromise the identity and thus confidentiality of the study participants since some categories of health providers had few interviewees per health facility.

3. Even though, the authors acknowledge that data from 2014 may be an issue but think that the results may still be relevant. I am particularly concerned because MTCT has gone through a number of transitions in the last decade. The last transition is the change to Dolutegravir with the attendant issues family planning particularly in the initial phase. In addition, viral load monitoring has become the standard of care compared to CD4 count. The implication of the results must be situated within the current context. This was not done.

We have included this information in the introduction (lines 70-73 and 78-81 on pages 3-4) and revised the limitations section to further situate our findings in the current contexts as highlighted by the reviewer. Please see changes made in lines 757-761 on page 32.

Reviewer #2: Thank you for this interesting manuscript. Please do a final editorial review after addressing the comments.

Thank you so much for the complement. We have done an editorial review of the manuscript after addressing all the comments.

Abstract: Methods:

The authors note that there were 54 key informant interviews with providers from 6 facilities – in the manuscript, it seems that the key informants extend beyond providers, including for example expert clients (which is great for data quality) – please make this clear in abstract. Or is the term “provider” being used to include all these categories of informants?

Yes, the term “health provider” was used to mean all the categories of individuals who provided health services to the HIV positive pregnant and breastfeeding women, and their infants. We have clarified this in the abstract in lines 36 and 38 on page 2, and under the study population in the methods section (lines 135-156 on pages 6-7).

Introduction:

Historical background to ART initiation in Uganda well documented, and rationale for manuscript well presented.

Thank you.

Methods:

Study sites: Do ethics requirements allow for facilities to be named? Double check study requirements regarding identifiers and protecting confidentiality of providers. Section on ethical consideration says they were assured of confidentiality.

The ethics committee allows the health facilities to be named. The providers were de-identified by removing the names of the health facilities from the quotes to ensure confidentiality.

Study population: See comment in abstract – It is a bit confusing who the participants in this study were – the authors say 54 key informant participants were included – and then lists them (Lines 129-131) – then later, Line 137, they say 54 health providers and 57 HIV positive women were enrolled. Are the initial 54 key informant participants the same as the 54 health providers? Please make this description clearer? In the results section, it is confirmed that the 54 key informants are as they are first listed in this section. Thanks for clarifying what expert clients are. What are store assistants?

We have clarified the study population in the methods section to clearly indicate that the participants were health providers and included expert clients. We have further created two sub-sections (selection of study participants and study context) to improve clarity. Please see lines 135-161, on pages 6-7.

Stores assistants (Assistant inventory management officer) have training in procurement and supply chain management. They carry out store management, stock layout, ordering, stock taking, issue and requisition, equipment inventory, re-distribution of drugs and prepare monthly stock status reports.

Line 133: Sentence starting “This study was part of…” – perhaps this should be the start of a new paragraph? Or clearly distinguish what is part of the study reported on in this manuscript, and what is the bigger study?

The sentence “This study was part of…” is starting on a new paragraph and we have clarified on the focus of the current manuscript in lines 162-173 on page 7.

Lines 138-140: Once the details of the participants (all providers, or other key informants too) are clarified, make sure that this sentence outlining the aim of the manuscript is in line with this (provider’s perspective only?).

The study participants for this manuscript have been clarified. These were the 54 health providers (formal and informal). Please see lines 135-161, on pages 6-7.

Data management and analysis (and elsewhere): Where author’s initials are used, standardise if they are written with periods/full stops or not (AM vs A.M).

We have standardized the author’s initials by writing them with periods such as, A.M. throughout the manuscript.

Results:

Figure 1 quality is not very good – quite hard to read.

We have revised figure 1 to improve its quality and ensured that it is readable.

Countermeasures – are these only described when reported on? It would be helpful to highlight this, as under most challenges they are described, and others there is no mention of how providers deal with the challenges.

To minimize the textual descriptions in the manuscript, we described the countermeasures for the challenges that were key. We included a visual lay out of the detailed challenges and countermeasures (Figure 1).

Descriptions in results – in some places these can be consolidated and summarised, as the illustrative quote gives the details – to double check that the summary point is not repetitive of what is reported in the quote (e.g. Lines 409-413: the countermeasure description could possibly be summarised as follows: “Participants reported that some clients were given additional ARV supplies to reduce visits to clinics for collection of medication” followed by the quote) – to check all.

We have checked all the results to ensure that the countermeasure descriptions are summarized where possible and that there are no repetitions in the summary point and quote. Please see lines 250-582, on pages 12-25.

Inadequacy of HIV service delivery and countermeasures:

Health worker related: Lack of relevant training:

Line 207: This quote is from a supplies officer, since the different categories of staff were interviewed, it may be helpful to specify in the quote identifier that it was a supplies officer at a hospital, not a health provider?

Supplies officers are also health providers. A supplies officer is the same as a stores’ assistant (Assistant inventory management officer). Specifying the quote identifier would compromise confidentiality since there were only two hospitals involved.

Are there any quotes/data to support the feedback of supervision and mentorship which were being done every 3 months?

We have included a quote on supervision and mentorship. Please see lines 268-270, on page 13.

The limited training seems to indicate that not many people are exposed to this?

Yes, this is a challenge as also highlighted that certain categories of staff were excluded from the training. Lines 255-257 on pages 11-12.

Shortage of health providers:

Line 219: Women – replace with female clients?

We have replaced “women” with female clients (lines 275 and 277 on page 13).

Line 220: Elaborate – how do long queues affect staff attitudes? Make them tired, flustered – this is linked closely to heavy workload. If too few staff, workload is more? Describe/distinguish the overlap between these points.

We have joined shortage of health providers and heavy work load so as to create a link between the two points. We have also made the points clearer. Lines 266-278 on pages 12-13.

Logistics and infrastructure related: Lack of guidelines

It seems like the guidelines do exist, it is that there are a lack of hardcopies of these guidelines? This also links to training on guidelines – if people are aware of the guidelines, they only need to refer to hardcopies for points of clarification?

This is true and we have revised the statement in the results section on page 15, lines 332-333. We have also included text in the discussion on page 29, lines 680-681.

Insufficient funds:

What should the source of these funds be? Is it budget allowance from government?

Line 303-305: Who funds these activities if there is limited funding? NGOs? Individual healthcare providers?

Most funding for PMTCT activities in Uganda is by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the global fund through the Uganda Ministry of Health.

Non-utilisation of HIV services and countermeasures:

HIV related stigma: Non-disclosure of HIV positive status

Line 333: perhaps reword – “fear of marriage breakages” to “fear of negative impact on relationships” – this extends to multiple partnerships scenarios, and the example given is about a marriage break-up.

We have reworded “fear of marriage breakages” to “fear of negative impact on relationships”. Lines 396-397 on page 18.

Fear to be followed-up: Is this follow-up referring to treatment adherence follow-up, linkage to care, reminders to come for clinic visits, or what kind of follow up? It would be helpful to know what is being referred to here?

The follow-up refers to follow-up for any HIV services. This was done especially for women and/or their infants who missed scheduled clinic appointments, and those from far places. It was done through; phone calls, home visits and community out-reaches.

Unwillingness to be linked to other intra-facility service care points:

Line 367: What is EID? Make sure all acronyms in full first time.

EID is early infant diagnosis. We wrote this in full in table 1 on page 9.

Suboptimal treatment adherence and countermeasures:

ART related: Preference for herbs:

Should this section “preference for herbs” be reclassified as “preference for traditional medicines”? Is the use of herbs about using traditional medicines?

We have reclassified “preference for herbs” as “preference for traditional medicines” in lines 43,506, and 513-514.

Male spouse related: Fear of spousal reaction:

This section seems to be very closely related to the section on stigma and non-disclosure – which was because of fear of spousal reaction, resulting in non-adherence? How were these themes differentiated? The link and distinction needs to be noted.

We agree, there is a close link between non-disclosure of HIV positive results to fear of spousal reaction under HIV-related stigma. We have shifted fear of spousal reaction from lines 523-533 on page 23 to the sub section of non-disclosure on page 17 lines 391-404.

Low male partner involvement in care:

Lines 469-496: The countermeasures described here are really important, in many African country settings, these ANC and delivery services are not set up to accommodate male partners attending these services with their female partners. This can be highlighted in the discussion.

We have highlighted the importance of the countermeasures under low male involvement in African countries in the discussion section on page 31, lines 749-751.

Discussion:

The authors note numerous really important recommendations throughout the discussion. Are there any considerations for how to take these recommendations forward – should there be government level strategizing, call for funding to increase budgets, further research, or how can these recommendations be implemented? (the last sentence of the conclusion section highlights research on the effectiveness of the countermeasures, which addresses this).

We thank you for noting this.

Fear of spousal reaction and low male partner involvement in care:

Line 640: Reference this first sentence.

We referenced the first sentence. Please see page 31 line 731 (references 60 and 61). The references are

1. Mosha I, Ruben R, Kakoko D. Family planning decisions, perceptions and gender dynamics among couples in Mwanza, Tanzania: a qualitative study. BMC public health. 2013;13(1):1-13.

2. Yargawa J, Leonardi-Bee J. Male involvement and maternal health outcomes: systematic review and meta-analysis. Journal of Epidemiology and Community Health. 2015;69(6):604-12. doi: 10.1136/jech-2014-204784

Strengths and limitations:

To add that only “providers” were interviewed – client perspectives could have added value to the results.

We also interviewed clients and captured their perspectives in regards to ART uptake, adherence, HIV positive status disclosure, and HIV-related stigma were published in other papers mentioned below. We referenced these papers in our manuscript (page 7, lines 166-169 and page 26, lines 609-610)

1. Buregyeya, E., Naigino, R., Mukose, A., Makumbi, F., Esiru, G., Arinaitwe, J., Musinguzi, J. and Wanyenze, R.K., 2017. Facilitators and barriers to uptake and adherence to lifelong antiretroviral therapy among HIV infected pregnant women in Uganda: a qualitative study. BMC pregnancy and childbirth, 17(1), pp.1-9.

2. Naigino, R., Makumbi, F., Mukose, A., Buregyeya, E., Arinaitwe, J., Musinguzi, J. and Wanyenze, R.K., 2017. HIV status disclosure and associated outcomes among pregnant women enrolled in antiretroviral therapy in Uganda: a mixed methods study. Reproductive health, 14(1), pp.1-11.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Desmond Kuupiel

31 Oct 2022

PONE-D-22-14861R1Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspectivePLOS ONE

Dear Dr. Mukose,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 29th November 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Desmond Kuupiel, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors response adequately addresses the comments raised. The manuscript is much clearer. However, the authors need to correct the error regarding Reference 2 and 3 . Otherwise, the manuscript is good to go

Reviewer #2: Thank you for addressing the review comments. I only have a few minor additional comments.

Please do a final copy edit before finalising.

Introduction:

Lines 87-91: Revision describing that MTCT of HIV should have declined due to revised treatment guidelines – the example demonstrating that it has not declined, uses data from 2017-2019, yet the guidelines were only implemented in 2020 (Line 78). Perhaps authors should find more recent data on MTCT rate in Uganda, or revise the wording of the paragraph.

Methods:

Study population: The study population selection and participation is much clearer now, thank you.

Results:

Line 229: Insert missing words: “Table 2 shows the details of the health providers who participated…”

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jan 20;18(1):e0280893. doi: 10.1371/journal.pone.0280893.r004

Author response to Decision Letter 1


8 Nov 2022

PONE-D-22-14861R1

Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspective

Dear Academic Editor,

Thank you so much for all the additional comments and suggestions that were raised during the review of the re-submitted manuscript. We thank the reviewers for all the comments. They have enabled us to improve our manuscript further.

We have addressed all comments in the “Point by point” response letter below. The changes are in track changes in the file labeled “Revised Manuscript with Track Changes”.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We have included all the above items.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We have not made any changes to the financial disclosure.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

We have reviewed the reference list to ensure that it is complete and correct.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

______________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

_______________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors response adequately addresses the comments raised. The manuscript is much clearer. However, the authors need to correct the error regarding Reference 2 and 3 Otherwise, the manuscript is good to go

Thank you. We have corrected the error in the references. They are now referenced 2 (Lines 771-772) and 4 (Lines 778-779).

Reviewer #2: Thank you for addressing the review comments. I only have a few minor additional comments.

Please do a final copy edit before finalising.

Thank you. We have edited the final copy of the manuscript.

Introduction:

Lines 87-91: Revision describing that MTCT of HIV should have declined due to revised treatment guidelines – the example demonstrating that it has not declined, uses data from 2017-2019, yet the guidelines were only implemented in 2020 (Line 78). Perhaps authors should find more recent data on MTCT rate in Uganda, or revise the wording of the paragraph.

We have revised the wording and included more recent data as well (Lines 95-102).

Methods:

Study population: The study population selection and participation is much clearer now, thank you.

Thank you very much.

Results:

Line 229: Insert missing words: “Table 2 shows the details of the health providers who participated…”

We have revised the wording of the statements (Lines 221 and 227).

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Desmond Kuupiel

11 Jan 2023

Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspective

PONE-D-22-14861R2

Dear Dr. Mukose,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Desmond Kuupiel, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Desmond Kuupiel

12 Jan 2023

PONE-D-22-14861R2

Challenges and commonly used countermeasures in the implementation of lifelong antiretroviral therapy for PMTCT in Central Uganda: Health providers’ perspective

Dear Dr. Mukose:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Desmond Kuupiel

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Due to restrictions by the Makerere University School of Public Health Higher Degrees, Research and Ethics Committee, some access restrictions apply to the data for reasons of safety and protection of study subjects and their institutions. Sensitive qualitative data was collected from study participants and they didn’t consent to open data access. However, criteria eligible researchers with interest in the data may request for anonymized data access through the Chair Higher Degrees, Research and Ethics Committee (contact via sphrecadmin@musph.ac.ug and cc:jkagaayi@musph.ac.ug).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES